Concentration of Protein Manufacturing Sites and Stable Supply Risk
First written in FY2021. 1 of 2 entries say "Mitigated", first in FY2022. Latest entry: FY2022.
The whole theme swung hardest in 2020: 4 of 20 companies on the "Worse" side.
5 other companies' latest entry also says "Mitigated".
- FY2022MitigatedAnnual report
「We are preparing to secure alternative production sites in addition to our manufacturing contractor and continue efforts to mitigate the risk.」
Although the proportion of merchandise sales to members increased from 58.9% to 59.6%, preparations are under way to secure alternative production sites for Protein. - FY2021First statedAnnual report
「Sales of merchandise to members amounted to ¥14,543 million in the consolidated fiscal year, accounting for 58.9% of consolidated net sales (fiscal year ended August 2021) and constituting a significant source of revenue for our Group. Protein, one of our main products, is produced on an OEM basis under a manufacturing outsourcing agreement with 日成共益株式会社, and production depends on that contractor.」
The structure has been quantified in which merchandise sales to members account for 58.9% of consolidated net sales and OEM production of the main product, Protein, depends on a single company.